Healthcare / Medical DevicesNasdaqGS
$5.43
-0.15 (-2.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-40.5M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$144M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-135.6%
↓Gross Margin
85.3%
↑Debt/Equity
1.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+56.4%
FCF CAGR
—
FCF margin
-71.9%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $56.7M · net income $-53.3M · FCF $-40.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $56.7M | $56.7M | $51.3M | $39.3M | $22.5M | $13.0M | $6.1M |
| Net Income | $-53.3M | $-53.3M | $-60.0M | $-41.2M | $-41.4M | $-43.1M | $-14.1M |
| EBITDA | $-46.7M | $-46.7M | $-54.9M | $-38.7M | $-40.7M | — | — |
| EPS | -2.04 | -2.04 | -2.65 | -1.99 | -2.02 | -4.16 | — |
| Gross Margin | 85.3% | 85.3% | 83.8% | 84.1% | 77.8% | 72.1% | 76.2% |
| Operating Margin | -90.5% | -90.5% | -116.0% | -109.7% | -189.3% | -199.2% | -190.2% |
| Net Margin | -94.1% | -94.1% | -116.9% | -104.8% | -184.4% | -330.5% | -233.1% |
| Balance Sheet | |||||||
| Debt/Equity | 1.28 | 1.28 | 0.71 | 0.40 | 0.06 | 0.00 | -0.07 |
| Current Ratio | 10.20 | 10.20 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-40.8M | $-40.8M | $-40.5M | $-39.6M | $-43.4M | $-28.9M | $-16.4M |
| Returns | |||||||
| ROE | -135.6% | -135.6% | -84.4% | -54.2% | -37.9% | -29.5% | 4.8% |
| Valuation | |||||||
| P/B | 3.60 | 3.60 | 4.34 | 8.09 | 3.10 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 10.4% | 10.4% | 30.5% | 74.9% | — | 115.4% | — |
| EPS Growth | 23.0% | 23.0% | -33.2% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.65 → -2.04
Residual
-18.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.